lutetium (177lu) chloride billev (previously illuzyce)
billev pharma aps - lutetium (177lu) chloride - radionuklidbilleddannelse - terapeutiske radioaktive lægemidler - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.
zerbaxa
merck sharp & dohme b.v. - ceftolozane sulfat, natrium tazobactam - bakterieinfektioner - antibakterielle midler til systemisk brug, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap). det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..
botox 100 enheder pulver til injektionsvæske, opløsning
europharma.dk aps - clostridium botulinum, type a toxin - pulver til injektionsvæske, opløsning - 100 enheder
latanoprost "upjohn" 50 mikrogram/ml øjendråber, opløsning
upjohn eesv - latanoprost - øjendråber, opløsning - 50 mikrogram/ml
paclitaxel "pharmachemie" 6 mg/ml koncentrat til infusionsvæske, opløsning
pharmachemie b.v. - paclitaxel - koncentrat til infusionsvæske, opløsning - 6 mg/ml
glyphomax vandopløseligt koncentrat
dow agrosciences danmark a/s - glyphosat - vandopløseligt koncentrat - 360 g/l glyphosat
glyphomax 480 vandopløseligt koncentrat
dow agrosciences danmark a/s - glyphosat - vandopløseligt koncentrat - 480 g/l glyphosat
glyphomax plus vandopløseligt koncentrat
dow agrosciences danmark a/s - glyphosat - vandopløseligt koncentrat - 360 g/l glyphosat
regent wg vanddispergerbart granulat
basf a/s - fipronil - vanddispergerbart granulat - 800 g/kg fipronil
evkeeza
ultragenyx germany gmbh - evinacumab - hyperkolesterolæmi - lipid modificerende midler - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).